There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Iovance Biotherapeutics Inc (IOVA) and Emergent Biosolutions (EBS) with bullish sentiments.
Iovance Biotherapeutics Inc (IOVA)
In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Iovance Biotherapeutics Inc, with a price target of $30. The company’s shares closed yesterday at $25.17, close to its 52-week high of $26.59.
Livshits commented:
“We therefore expect further visibility on a regulatory path in Europe for both melanoma and cervical in 2020.”
According to TipRanks.com, Livshits is a 4-star analyst with an average return of 23.5% and a 76.2% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Logicbio Therapeutics Inc, Crispr Therapeutics AG, and Intellia Therapeutics.
Currently, the analyst consensus on Iovance Biotherapeutics Inc is a Strong Buy with an average price target of $30.88, which is a 22.7% upside from current levels. In a report released yesterday, Cowen & Co. also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Emergent Biosolutions (EBS)
In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Emergent Biosolutions, with a price target of $71. The company’s shares closed yesterday at $44.19, close to its 52-week low of $39.64.
Nakae wrote:
“We would note that BioThrax sales exhibit significant variability from quarter to quarter. This is being further exacerbated this year as the anthrax vaccine product supply for placement into the Strategic National Stockpile (SNS) transitions from BioThrax to AV7909 (aka NuThrax). Back in May, BARDA informed the Company that it will begin procuring an initial three million doses of AV7909, which the Company will begin to deliver in Q3. Sales of other Biodefense products increased to $156 MM (+52%) compared to $103 MM a year ago, largely driven by the contribution from sales of MM, which was acquired in Q4 2018. ACAM2000 sales were $6.5 MM. Revenue from contract manufacturing operations was $19 MM (-21%), reflecting a difficult comparable to one-time orders a year ago.”
According to TipRanks.com, Nakae ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -10.2% and a 31.5% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Arcturus Therapeutics Ltd, and Arrowhead Research.
Currently, the analyst consensus on Emergent Biosolutions is a Moderate Buy with an average price target of $64.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
